Live Earnings Conference Call: Supernus Pharmaceuticals will host a live Q1 2025 earnings call on May 6, 2025 at 4:30PM ET. Get details.

Supernus Pharmaceuticals (SUPN) Financials

$32.39 -0.45 (-1.37%)

Closing price 05/5/2025 04:00 PM Eastern

Extended Trading

$33.49 +1.10 (+3.40%)

As of 04:24 AM Eastern

Compare

Annual Income Statements for Supernus Pharmaceuticals

This table shows Supernus Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-11	14	511	57	111	113	127	53	61	1.32	74
Consolidated Net Income / (Loss)	-11	14	91	57	111	113	127	53	61	1.32	74
Net Income / (Loss) Continuing Operations	-11	14	511	57	111	113	127	53	61	1.32	74
Total Pre-Tax Income	-10	15	50	101	140	147	169	73	61	2.77	98
Total Operating Income	-5.28	21	54	100	144	149	174	86	46	-5.27	82
Total Gross Profit	87	139	413	287	394	376	468	505	580	524	584
Total Revenue	93	147	425	302	409	393	520	580	667	608	662
Operating Revenue	93	147	425	302	409	393	520	580	667	608	662
Total Cost of Revenue	5.76	8.42	12	15	15	17	52	75	87	84	78
Operating Cost of Revenue	5.76	8.42	12	15	15	17	52	75	87	84	78
Total Operating Expenses	92	118	-61	187	249	228	294	419	534	529	502
Selling, General & Admin Expense	73	89	106	138	155	153	201	305	377	336	322
Research & Development Expense	20	29	43	50	89	69	76	90	75	92	109
Amortization Expense	-	-	-	-	5.19	5.18	16	30	83	82	78
Impairment Charge	-	-	-	-	-	-	-	-	0.00	20	0.00
Other Special Charges / (Income)	-	-	-	-	0.00	0.00	1.90	-6.53	-0.51	-1.52	-6.11
Total Other Income / (Expense), net	-5.02	-6.23	-3.85	1.08	-4.27	-1.08	-5.05	-13	15	8.04	16
Interest Expense	8.21	7.11	5.76	-	-	-	-	-	7.07	2.42	0.00
Other Income / (Expense), net	2.85	0.19	0.45	1.08	-4.27	-1.08	-5.05	-13	22	10	16
Income Tax Expense	0.63	0.67	-41	43	29	34	42	20	0.03	1.45	24
Basic Earnings per Share	($0.26)	$0.29	$1.84	$1.13	$2.13	$2.16	$2.41	$1.01	$1.13	$0.02	$1.34
Weighted Average Basic Shares Outstanding	42.26M	47.49M	49.47M	50.76M	51.99M	52.41M	52.62M	53.10M	53.67M	54.54M	55.10M
Diluted Earnings per Share	($0.26)	$0.28	$1.76	$1.08	$2.05	$2.10	$2.36	$0.98	$1.04	$0.02	$1.32
Weighted Average Diluted Shares Outstanding	42.26M	51.16M	51.71M	53.30M	54.10M	53.82M	53.69M	54.36M	61.68M	55.51M	55.96M
Weighted Average Basic & Diluted Shares Outstanding	42.30M	48.10M	49.60M	51.54M	52.32M	52.53M	52.92M	53.39M	54.38M	-	55.81M

This table shows Supernus Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	1.75	25	17	-0.83	-16	1.18	0.12	20	38	15
Consolidated Net Income / (Loss)	1.75	25	17	-0.83	-16	1.18	0.12	20	38	15
Net Income / (Loss) Continuing Operations	1.75	25	17	-0.83	-16	1.18	0.12	20	38	15
Total Pre-Tax Income	-0.44	35	9.02	-17	9.89	0.99	0.24	26	45	26
Total Operating Income	-1.52	34	5.18	-18	8.14	-1.00	-3.15	23	41	21
Total Gross Profit	151	144	130	114	134	145	127	150	158	148
Total Revenue	177	167	154	136	154	164	144	168	176	174
Operating Revenue	177	167	154	136	154	164	144	168	176	174
Total Cost of Revenue	26	23	23	21	20	20	16	18	18	26
Operating Cost of Revenue	26	23	23	21	20	20	16	18	18	26
Total Operating Expenses	153	110	125	132	126	146	130	128	117	127
Selling, General & Admin Expense	112	74	86	87	83	81	87	86	70	79
Research & Development Expense	20	18	21	24	23	23	25	26	29	29
Amortization Expense	21	21	20	20	21	21	20	20	19	18
Other Special Charges / (Income)	0.49	-2.40	-1.65	0.79	-0.46	-0.20	-1.10	-4.36	-1.02	0.36
Total Other Income / (Expense), net	1.08	0.81	3.84	0.46	1.75	1.99	3.40	3.73	4.10	4.98
Other Income / (Expense), net	2.80	2.40	5.35	1.37	1.75	1.99	3.40	3.73	4.10	4.98
Income Tax Expense	-2.19	9.66	-7.93	-16	26	-0.19	0.12	6.39	6.45	11
Basic Earnings per Share	$0.03	$0.47	$0.31	($0.02)	($0.29)	$0.02	$0.00	$0.36	$0.70	$0.28
Weighted Average Basic Shares Outstanding	53.79M	53.67M	54.38M	54.50M	54.61M	54.54M	54.80M	54.98M	55.15M	55.10M
Diluted Earnings per Share	$0.03	$0.44	$0.29	($0.02)	($0.29)	$0.04	$0.00	$0.36	$0.69	$0.27
Weighted Average Diluted Shares Outstanding	55.03M	61.68M	62.45M	54.50M	54.61M	55.51M	55.63M	55.72M	56.02M	55.96M
Weighted Average Basic & Diluted Shares Outstanding	54.06M	54.38M	54.48M	54.59M	54.63M	0.00	54.97M	55.11M	55.22M	55.81M

This table details how cash moves in and out of Supernus Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	3.42	-2.90	-58	34	92	-11	107	-85	-110	-18	-5.72
Net Cash From Operating Activities	-24	35	67	115	129	143	138	127	117	111	172
Net Cash From Continuing Operating Activities	-24	35	-24	115	129	143	138	127	117	111	172
Net Income / (Loss) Continuing Operations	-11	14	0.00	57	111	113	127	53	61	1.32	74
Consolidated Net Income / (Loss)	-11	14	-	57	111	113	127	53	61	1.32	74
Depreciation Expense	0.93	0.92	2.40	8.13	7.06	6.66	18	33	86	85	80
Amortization Expense	2.09	0.75	0.52	-0.51	10	12	14	18	5.35	0.41	1.82
Non-Cash Adjustments To Reconcile Net Income	13	25	22	31	48	17	14	31	16	61	59
Changes in Operating Assets and Liabilities, net	-29	-6.35	-49	18	-48	-5.03	-34	-7.95	-51	-36	-43
Net Cash From Investing Activities	-2.66	-39	-36	-86	-413	-158	-35	-82	-217	269	-190
Net Cash From Continuing Investing Activities	-2.66	-39	-36	-86	-413	-158	-35	-82	-217	269	-190
Purchase of Property, Plant & Equipment	-0.59	-2.10	-1.60	-2.03	-0.84	-1.39	-3.69	-2.05	-0.41	-0.55	-0.73
Purchase of Investments	-53	-64	-47	-102	-492	-410	-96	-312	-407	-102	-688
Sale and/or Maturity of Investments	53	38	32	29	80	253	378	531	191	371	499
Net Cash From Financing Activities	31	1.87	2.05	5.68	376	3.93	3.56	-130	-10	-398	12
Net Cash From Continuing Financing Activities	31	1.87	2.05	5.68	376	3.93	3.56	-130	-10	-398	12
Repayment of Debt	-	-	-	-	-	0.00	0.00	-138	0.00	-496	0.00
Issuance of Debt	0.00	-	-	0.00	403	-	-	-	0.00	93	0.00
Issuance of Common Equity	0.57	1.87	2.05	5.68	77	3.93	4.36	7.10	12	6.61	15
Other Financing Activities, net	30	-	-	0.00	-93	0.00	-0.80	0.80	-23	-1.99	-2.72
Cash Interest Paid	2.85	0.83	0.49	0.13	1.34	2.52	2.52	2.52	2.52	1.95	0.00
Cash Income Taxes Paid	-	-	-	1.59	35	52	45	25	16	37	53

This table details how cash moves in and out of Supernus Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-62	-18	369	-437	70	-20	-12	-11	-20	38
Net Cash From Operating Activities	14	28	49	-19	36	45	38	36	54	44
Net Cash From Continuing Operating Activities	14	28	49	-19	36	45	38	36	54	44
Net Income / (Loss) Continuing Operations	1.75	25	17	-0.83	-16	1.18	0.12	20	38	15
Consolidated Net Income / (Loss)	1.75	25	17	-0.83	-16	1.18	0.12	20	38	15
Depreciation Expense	22	21	21	21	22	22	21	21	20	19
Amortization Expense	2.68	0.55	-0.52	0.14	0.07	0.73	1.89	-0.36	0.97	-0.67
Non-Cash Adjustments To Reconcile Net Income	3.22	7.92	8.77	12	9.98	30	8.35	11	24	15
Changes in Operating Assets and Liabilities, net	-16	-27	3.34	-51	20	-8.69	7.29	-15	-30	-4.43
Net Cash From Investing Activities	-82	-49	240	60	35	-66	-52	-49	-77	-13
Net Cash From Continuing Investing Activities	-82	-49	240	60	35	-66	-52	-49	-77	-13
Purchase of Property, Plant & Equipment	-0.15	0.01	-0.28	-0.16	-0.15	0.04	-0.25	-0.06	-0.20	-0.21
Purchase of Investments	-134	-66	0.00	-	-	-102	-194	-124	-225	-145
Sale and/or Maturity of Investments	52	18	240	60	35	36	142	75	148	133
Net Cash From Financing Activities	6.46	2.83	80	-479	-0.23	1.09	1.57	1.66	3.08	5.89
Net Cash From Continuing Financing Activities	6.46	2.83	80	-479	-0.23	1.09	1.57	1.66	3.08	5.89
Issuance of Common Equity	6.46	2.83	2.26	2.52	0.74	1.09	2.91	1.66	3.46	6.88
Other Financing Activities, net	-	-	-0.45	-0.58	-0.97	-	-1.34	-0.00	-0.39	-0.99
Cash Income Taxes Paid	6.02	1.64	0.20	20	6.62	9.55	0.34	20	20	13

This table presents Supernus Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	137	189	310	424	978	1,160	1,504	1,689	1,703	1,278	1,368
Total Current Assets	109	106	151	228	493	473	630	602	734	493	686
Cash & Equivalents	36	33	66	100	192	181	289	203	93	75	69
Short-Term Investments	38	29	24	40	164	166	134	136	368	180	384
Accounts Receivable	17	26	42	66	103	87	141	149	165	144	142
Inventories, net	13	13	17	16	26	27	48	86	92	77	54
Prepaid Expenses	3.68	5.26	2.96	6.52	8.89	12	19	27	16	17	36
Plant, Property, & Equipment, net	2.45	3.87	4.34	5.12	4.10	17	0.00	0.00	15	14	12
Total Noncurrent Assets	26	79	154	191	480	671	874	1,088	953	771	670
Long-Term Investments	20	55	75	134	419	592	350	119	94	17	0.00
Goodwill	-	-	-	-	-	0.00	78	118	117	117	117
Intangible Assets	0.23	0.98	36	36	31	25	364	785	702	600	522
Other Noncurrent Operating Assets	5.57	23	0.33	0.39	0.38	22	81	66	40	38	32
Total Liabilities & Shareholders' Equity	137	189	310	424	978	1,160	1,504	1,689	1,703	1,278	1,368
Total Liabilities	96	101	118	157	525	565	759	873	816	356	332
Total Current Liabilities	28	57	81	123	161	161	245	315	688	290	292
Short-Term Debt	-	-	-	-	-	0.00	31	45	423	52	47
Accounts Payable	1.86	4.31	8.06	6.84	40	50	79	118	96	80	76
Accrued Expenses	26	52	69	96	107	108	126	133	152	154	169
Other Current Liabilities	-	0.50	3.10	4.28	2.18	3.24	9.08	20	17	4.28	0.00
Total Noncurrent Liabilities	68	44	37	34	363	404	514	558	128	66	40
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	-	-	-	0.00	35	85	50	25	4.96
Other Noncurrent Operating Liabilities	40	35	31	33	34	59	89	52	79	41	35
Commitments & Contingencies	-	-	-	-	-	-	-	-	-	0.00	0.00
Total Equity & Noncontrolling Interests	41	88	192	267	453	595	745	816	886	922	1,036
Total Preferred & Common Equity	41	88	192	267	453	595	745	816	886	922	1,036
Total Common Equity	41	88	192	267	453	595	745	816	886	922	1,036
Common Stock	230	264	276	295	370	388	409	434	408	440	479
Retained Earnings	-189	-176	-84	-27	86	200	326	380	481	483	556
Accumulated Other Comprehensive Income / (Loss)	-0.15	-0.49	-0.13	-0.75	-3.16	7.42	8.98	1.54	-3.21	-0.59	-0.19

This table presents Supernus Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	1,693	1,792	1,293	1,285	1,304	1,316	1,343
Total Current Assets	664	883	424	449	544	591	640
Cash & Equivalents	111	58	25	95	63	52	32
Short-Term Investments	280	170	127	105	234	295	372
Accounts Receivable	164	144	137	142	148	152	145
Inventories, net	83	91	91	83	75	68	64
Prepaid Expenses	25	16	45	24	24	23	27
Plant, Property, & Equipment, net	0.00	15	14	14	13	12	12
Total Noncurrent Assets	1,029	894	855	822	747	713	691
Long-Term Investments	132	54	37	25	12	0.00	0.00
Goodwill	117	117	117	117	117	117	117
Intangible Assets	723	682	662	641	580	560	540
Other Noncurrent Operating Assets	57	40	38	39	38	36	34
Total Liabilities & Shareholders' Equity	1,693	1,792	1,293	1,285	1,304	1,316	1,343
Total Liabilities	840	880	373	373	375	358	336
Total Current Liabilities	726	732	253	288	315	309	292
Short-Term Debt	449	481	21	46	51	47	47
Accounts Payable	110	95	83	78	86	83	76
Accrued Expenses	158	148	149	162	167	175	169
Other Current Liabilities	8.19	7.49	0.00	0.71	9.55	3.62	0.00
Total Noncurrent Liabilities	114	148	121	85	60	50	44
Noncurrent Deferred & Payable Income Tax Liabilities	58	50	44	35	20	11	7.36
Other Noncurrent Operating Liabilities	56	98	76	50	41	38	37
Commitments & Contingencies	-	-	-	-	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	853	912	920	912	929	957	1,007
Total Preferred & Common Equity	853	912	920	912	929	957	1,007
Total Common Equity	853	912	920	912	929	957	1,007
Common Stock	401	416	424	432	447	455	466
Retained Earnings	456	498	497	481	483	503	541
Accumulated Other Comprehensive Income / (Loss)	-4.05	-2.33	-1.78	-1.21	-0.53	-0.37	0.08

This table displays calculated financial ratios and metrics derived from Supernus Pharmaceuticals' official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	671.10%	59.12%	188.26%	-28.90%	35.29%	-3.95%	32.50%	11.41%	15.09%	-8.95%	8.94%
EBITDA Growth	100.82%	3,761.56%	153.60%	87.97%	45.44%	5.33%	20.90%	-38.30%	28.31%	-43.00%	99.12%
EBIT Growth	96.77%	965.72%	159.85%	84.07%	39.32%	5.22%	14.35%	-56.61%	-7.33%	-92.36%	1,787.92%
NOPAT Growth	91.48%	638.46%	393.56%	-42.28%	101.82%	-0.42%	14.81%	-51.96%	-26.60%	-105.43%	2,561.33%
Net Income Growth	88.16%	227.63%	554.20%	-37.20%	93.76%	1.86%	12.29%	-57.92%	13.64%	-97.83%	5,512.84%
EPS Growth	91.03%	207.69%	528.57%	-38.64%	89.81%	2.44%	12.38%	-58.47%	6.12%	-98.08%	6,500.00%
Operating Cash Flow Growth	57.73%	240.94%	93.52%	71.59%	12.51%	10.96%	-3.30%	-8.14%	-8.10%	-4.91%	54.79%
Free Cash Flow Firm Growth	101.57%	3,216.30%	209.34%	104.10%	7.77%	19.20%	-317.60%	-40.55%	131.23%	-56.78%	171.46%
Invested Capital Growth	-17.93%	18.81%	237.46%	-120.40%	223.73%	-77.15%	22,342.69%	109.16%	-8.31%	-6.89%	-10.35%
Revenue Q/Q Growth	29.12%	9.22%	116.53%	-37.84%	8.86%	-4.59%	8.49%	2.75%	1.26%	-0.49%	0.00%
EBITDA Q/Q Growth	101.67%	8.49%	18.55%	22.13%	3.58%	0.59%	-6.21%	-19.05%	53.24%	-23.42%	0.00%
EBIT Q/Q Growth	93.72%	11.22%	18.20%	23.47%	0.89%	1.34%	-9.97%	-33.87%	333.56%	-84.69%	0.00%
NOPAT Q/Q Growth	75.74%	9.99%	7.20%	-2.66%	13.76%	5.97%	0.14%	-30.74%	89.18%	-112.00%	0.00%
Net Income Q/Q Growth	41.59%	28.19%	8.91%	-1.14%	12.39%	6.84%	-1.83%	-34.65%	61.16%	-94.86%	0.00%
EPS Q/Q Growth	83.65%	16.67%	11.39%	-3.57%	10.22%	7.14%	-1.67%	-35.10%	62.50%	-95.24%	0.00%
Operating Cash Flow Q/Q Growth	39.04%	65.50%	8.11%	11.04%	-2.63%	8.28%	-7.89%	15.26%	-15.36%	18.57%	0.00%
Free Cash Flow Firm Q/Q Growth	102.17%	122.85%	2.27%	22.71%	-6.47%	9.65%	10.91%	-329.50%	129.03%	-25.29%	63.27%
Invested Capital Q/Q Growth	-2.36%	-45.99%	-4.35%	-144.30%	8.43%	-66.82%	-8.23%	128.76%	-3.09%	-4.18%	-3.24%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	93.79%	94.29%	97.18%	94.97%	96.24%	95.76%	89.92%	87.05%	86.93%	86.21%	88.23%
EBITDA Margin	0.63%	15.40%	13.55%	35.81%	38.50%	42.22%	38.52%	21.33%	23.78%	14.89%	27.21%
Operating Margin	-5.70%	14.13%	12.75%	32.93%	35.33%	37.83%	33.38%	14.84%	6.91%	-0.87%	12.34%
EBIT Margin	-2.62%	14.27%	12.86%	33.29%	34.28%	37.55%	32.41%	12.62%	10.16%	0.85%	14.79%
Profit (Net Income) Margin	-11.79%	9.46%	21.46%	18.95%	27.14%	28.79%	24.39%	9.21%	9.10%	0.22%	11.16%
Tax Burden Percent	106.12%	95.44%	181.11%	56.93%	79.18%	76.65%	75.28%	73.01%	99.95%	47.53%	75.47%
Interest Burden Percent	423.66%	69.45%	92.14%	100.00%	100.00%	100.00%	100.00%	100.00%	89.57%	53.41%	100.00%
Effective Tax Rate	0.00%	4.56%	-81.11%	43.07%	20.82%	23.35%	24.72%	26.99%	0.05%	52.47%	24.53%
Return on Invested Capital (ROIC)	0.00%	0.00%	2,371.12%	468.53%	15,550.30%	2,417.73%	66.21%	10.33%	5.85%	-0.34%	9.26%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	2,376.25%	468.25%	15,551.24%	2,417.89%	67.02%	15.77%	-17.42%	-2.52%	5.35%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	-2,305.91%	-443.58%	-15,519.49%	-2,396.16%	-47.27%	-3.49%	1.29%	0.49%	-1.71%
Return on Equity (ROE)	-29.46%	21.67%	65.21%	24.95%	30.81%	21.57%	18.94%	6.85%	7.13%	0.15%	7.55%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	150.36%	0.00%	1,310.54%	2,543.34%	-132.01%	-60.28%	14.52%	6.79%	20.17%
Operating Return on Assets (OROA)	-1.96%	12.93%	21.94%	27.42%	19.99%	13.80%	12.66%	4.58%	4.00%	0.35%	7.40%
Return on Assets (ROA)	-8.82%	8.57%	36.62%	15.61%	15.83%	10.58%	9.53%	3.35%	3.58%	0.09%	5.58%
Return on Common Equity (ROCE)	-29.46%	21.67%	65.21%	24.95%	30.81%	21.57%	18.94%	6.85%	7.13%	0.15%	7.55%
Return on Equity Simple (ROE_SIMPLE)	-26.84%	15.84%	47.57%	21.42%	24.50%	18.99%	17.04%	6.55%	6.85%	0.14%	7.13%
Net Operating Profit after Tax (NOPAT)	-3.69	20	98	57	114	114	131	63	46	-2.50	62
NOPAT Margin	-3.99%	13.49%	23.10%	18.75%	27.97%	29.00%	25.13%	10.83%	6.91%	-0.41%	9.31%
Net Nonoperating Expense Percent (NNEP)	-11.62%	-6.68%	-5.13%	0.28%	-0.94%	-0.16%	-0.80%	-5.44%	23.27%	2.17%	3.91%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	3.52%	-0.26%	5.69%
Cost of Revenue to Revenue	6.21%	5.71%	2.82%	5.03%	3.76%	4.24%	10.08%	12.95%	13.07%	13.79%	11.77%
SG&A Expenses to Revenue	78.35%	60.40%	24.94%	45.63%	37.83%	39.02%	38.56%	52.57%	56.53%	55.37%	48.59%
R&D to Revenue	21.13%	19.76%	10.07%	16.40%	21.82%	17.59%	14.60%	15.60%	11.17%	15.08%	16.44%
Operating Expenses to Revenue	99.48%	80.15%	-14.42%	62.03%	60.92%	57.93%	56.54%	72.22%	80.02%	87.08%	75.89%
Earnings before Interest and Taxes (EBIT)	-2.43	21	55	101	140	147	169	73	68	5.18	98
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	0.59	23	58	108	157	166	200	124	159	90	180
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	8.76	7.47	6.52	7.64	3.83	2.09	1.78	1.90	2.18	1.72	1.93
Price to Tangible Book Value (P/TBV)	8.80	7.56	8.04	8.83	4.12	2.18	4.38	0.00	28.90	7.73	5.03
Price to Revenue (P/Rev)	3.84	4.46	2.94	6.76	4.25	3.17	2.55	2.67	2.89	2.60	3.02
Price to Earnings (P/E)	0.00	47.16	2.44	35.66	15.64	11.01	10.44	29.03	31.76	1,201.42	27.03
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	2.12%	40.91%	2.80%	6.39%	9.09%	9.58%	3.45%	3.15%	0.08%	3.70%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	35.83	0.00	168.29	371.43	2.48	1.89	2.38	1.94	2.53
Enterprise Value to Revenue (EV/Rev)	3.11	3.71	2.56	5.85	3.16	1.66	1.87	2.69	2.69	2.24	2.40
Enterprise Value to EBITDA (EV/EBITDA)	490.46	24.11	18.91	16.34	8.20	3.92	4.86	12.59	11.32	15.05	8.83
Enterprise Value to EBIT (EV/EBIT)	0.00	26.02	19.92	17.58	9.21	4.41	5.77	21.28	26.49	262.66	16.25
Enterprise Value to NOPAT (EV/NOPAT)	0.00	27.52	11.09	31.22	11.28	5.71	7.45	24.79	38.96	0.00	25.80
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	15.86	16.30	15.43	10.01	4.55	7.04	12.25	15.37	12.26	9.25
Enterprise Value to Free Cash Flow (EV/FCFF)	647.49	37.06	23.83	18.97	12.84	5.43	0.00	0.00	15.70	27.53	11.85
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.64	0.08	0.02	0.00	0.73	0.58	0.57	0.57	0.48	0.06	0.05
Long-Term Debt to Equity	0.64	0.08	0.02	0.00	0.73	0.58	0.52	0.52	0.00	0.00	0.00
Financial Leverage	-1.68	-1.38	-0.97	-0.95	-1.00	-0.99	-0.71	-0.22	-0.07	-0.19	-0.32
Leverage Ratio	3.34	2.53	1.78	1.60	1.95	2.04	1.99	2.05	1.99	1.65	1.35
Compound Leverage Factor	14.15	1.76	1.64	1.60	1.95	2.04	1.99	2.05	1.78	0.88	1.35
Debt to Total Capital	39.18%	7.45%	2.13%	0.00%	42.10%	36.70%	36.12%	36.32%	32.31%	5.35%	4.37%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.65%	3.50%	32.31%	5.35%	4.37%
Long-Term Debt to Total Capital	39.18%	7.45%	2.13%	0.00%	42.10%	36.70%	33.47%	32.82%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	60.82%	92.55%	97.87%	100.00%	57.90%	63.30%	63.88%	63.68%	67.69%	94.65%	95.63%
Debt to EBITDA	44.60	0.31	0.07	0.00	2.09	2.08	2.10	3.76	2.67	0.58	0.26
Net Debt to EBITDA	-115.53	-4.85	-2.80	0.00	-2.83	-3.58	-1.75	0.05	-0.83	-2.43	-2.26
Long-Term Debt to EBITDA	44.60	0.31	0.07	0.00	2.09	2.08	1.95	3.40	0.00	0.00	0.00
Debt to NOPAT	-7.10	0.36	0.04	0.00	2.88	3.03	3.22	7.41	9.18	-20.79	0.77
Net Debt to NOPAT	18.39	-5.54	-1.64	0.00	-3.89	-5.21	-2.69	0.10	-2.87	87.62	-6.59
Long-Term Debt to NOPAT	-7.10	0.36	0.04	0.00	2.88	3.03	2.99	6.70	0.00	0.00	0.00
Altman Z-Score	1.61	4.08	8.22	9.51	3.41	2.64	2.37	2.07	2.37	3.87	5.24
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.87	1.86	1.88	1.86	3.06	2.94	2.57	1.91	1.07	1.70	2.35
Quick Ratio	3.26	1.55	1.63	1.67	2.84	2.71	2.30	1.55	0.91	1.38	2.04
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.45	15	46	93	101	120	-261	-366	114	49	134
Operating Cash Flow to CapEx	-4,130.69%	1,640.87%	4,167.94%	5,650.07%	15,282.70%	10,319.32%	3,750.65%	6,216.48%	28,355.83%	20,160.62%	23,717.38%
Free Cash Flow to Firm to Interest Expense	0.05	2.08	7.93	0.00	0.00	0.00	0.00	0.00	16.19	20.48	0.00
Operating Cash Flow to Interest Expense	-2.98	4.86	11.60	0.00	0.00	0.00	0.00	0.00	16.52	46.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-3.05	4.56	11.32	0.00	0.00	0.00	0.00	0.00	16.47	45.77	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.75	0.91	1.71	0.82	0.58	0.37	0.39	0.36	0.39	0.41	0.50
Accounts Receivable Turnover	8.30	6.83	12.61	5.64	4.85	4.13	4.56	4.00	4.24	3.92	4.62
Inventory Turnover	0.56	0.65	0.82	0.92	0.73	0.64	1.40	1.12	0.98	0.99	1.18
Fixed Asset Turnover	37.06	46.65	103.45	63.84	88.71	37.12	0.00	0.00	0.00	42.33	52.79
Accounts Payable Turnover	2.30	2.73	1.94	2.04	0.66	0.37	0.82	0.76	0.82	0.95	1.00
Days Sales Outstanding (DSO)	43.96	53.44	28.95	64.68	75.21	88.40	80.03	91.23	86.00	93.02	78.93
Days Inventory Outstanding (DIO)	652.70	563.95	447.46	397.09	498.71	572.77	260.75	326.49	371.40	368.03	308.52
Days Payable Outstanding (DPO)	158.63	133.84	188.33	178.71	553.51	979.80	447.55	478.05	447.82	383.20	365.26
Cash Conversion Cycle (CCC)	538.02	483.55	288.08	283.05	20.41	-318.63	-106.77	-60.33	9.58	77.85	22.19
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-27	-22	30	-6.20	7.67	1.75	393	822	754	702	629
Invested Capital Turnover	-3.68	-5.98	102.65	24.99	555.94	83.38	2.64	0.95	0.85	0.83	0.99
Increase / (Decrease) in Invested Capital	-4.14	5.12	52	-37	14	-5.92	391	429	-68	-52	-73
Enterprise Value (EV)	288	547	1,089	1,769	1,291	651	974	1,557	1,796	1,362	1,590
Market Capitalization	356	658	1,250	2,043	1,736	1,244	1,326	1,551	1,928	1,581	1,997
Book Value per Share	$0.95	$1.80	$3.87	$5.22	$8.67	$11.35	$14.14	$15.34	$16.39	$16.87	$18.76
Tangible Book Value per Share	$0.94	$1.78	$3.14	$4.52	$8.07	$10.88	$5.74	($1.62)	$1.23	$3.75	$7.19
Total Capital	67	95	196	267	782	941	1,166	1,281	1,309	974	1,083
Total Debt	26	7.09	4.17	0.00	329	345	421	465	423	52	47
Total Long-Term Debt	26	7.09	4.17	0.00	329	345	390	421	0.00	0.00	0.00
Net Debt	-68	-110	-161	-274	-445	-594	-352	6.54	-132	-219	-406
Capital Expenditures (CapEx)	0.59	2.10	1.60	2.03	0.84	1.39	3.69	2.05	0.41	0.55	0.73
Debt-free, Cash-free Net Working Capital (DFCFNWC)	6.27	-13	-19	-35	-24	-35	-6.32	-8.63	7.95	0.11	-13
Debt-free Net Working Capital (DFNWC)	81	49	71	105	332	312	416	331	469	255	441
Net Working Capital (NWC)	81	49	71	105	332	312	385	286	46	203	394
Net Nonoperating Expense (NNE)	7.23	5.95	6.97	-0.61	3.38	0.83	3.80	9.38	-15	-3.82	-12
Net Nonoperating Obligations (NNO)	-68	-110	-161	-274	-445	-594	-352	6.54	-132	-219	-406
Total Depreciation and Amortization (D&A)	3.02	1.67	2.92	7.62	17	18	32	51	91	85	82
Debt-free, Cash-free Net Working Capital to Revenue	6.76%	-8.94%	-4.58%	-11.44%	-5.84%	-8.92%	-1.22%	-1.49%	1.19%	0.02%	-1.90%
Debt-free Net Working Capital to Revenue	86.97%	33.24%	16.62%	34.89%	81.23%	79.45%	79.98%	57.10%	70.33%	41.97%	66.64%
Net Working Capital to Revenue	86.97%	33.24%	16.62%	34.89%	81.23%	79.45%	74.04%	49.37%	6.92%	33.40%	59.48%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.47	$0.30	$1.84	$1.13	$2.13	$2.16	$2.41	$1.01	$1.13	$0.00	$1.34
Adjusted Weighted Average Basic Shares Outstanding	42.26M	47.49M	49.47M	50.76M	51.99M	52.41M	52.62M	53.10M	53.67M	0.00	55.10M
Adjusted Diluted Earnings per Share	$0.32	$0.28	$1.76	$1.08	$2.05	$2.10	$2.36	$0.98	$1.04	$0.00	$1.32
Adjusted Weighted Average Diluted Shares Outstanding	50.58M	51.16M	51.71M	53.30M	54.10M	53.82M	53.69M	54.36M	61.68M	0.00	55.96M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$2.16	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	44.09M	49.40M	50.16M	51.54M	52.32M	52.53M	52.92M	53.39M	54.38M	0.00	55.81M
Normalized Net Operating Profit after Tax (NOPAT)	-3.69	20	38	57	114	114	132	58	46	9.38	57
Normalized NOPAT Margin	-3.99%	13.49%	8.93%	18.75%	27.97%	29.00%	25.40%	10.01%	6.83%	1.54%	8.62%
Pre Tax Income Margin	-11.11%	9.91%	11.85%	33.29%	34.28%	37.55%	32.41%	12.62%	9.10%	0.46%	14.79%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-0.30	2.96	9.49	0.00	0.00	0.00	0.00	0.00	9.59	2.15	0.00
NOPAT to Interest Expense	-0.45	2.80	17.04	0.00	0.00	0.00	0.00	0.00	6.52	-1.04	0.00
EBIT Less CapEx to Interest Expense	-0.37	2.66	9.21	0.00	0.00	0.00	0.00	0.00	9.53	1.92	0.00
NOPAT Less CapEx to Interest Expense	-0.52	2.50	16.76	0.00	0.00	0.00	0.00	0.00	6.46	-1.27	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	9.40%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Supernus Pharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	19.46%	5.20%	0.82%	-20.28%	-13.24%	-1.80%	-6.58%	24.17%	14.17%	5.99%
EBITDA Growth	-45.82%	1,840.29%	-19.88%	-87.32%	23.64%	-59.76%	-25.21%	904.02%	107.49%	90.45%
EBIT Growth	-96.33%	337.95%	-36.86%	-223.47%	672.58%	-97.30%	-97.69%	262.19%	354.47%	2,564.85%
NOPAT Growth	-104.39%	242.90%	184.27%	-256.22%	-1,133.21%	-104.75%	-116.54%	238.81%	366.12%	1,152.04%
Net Income Growth	-91.89%	943.45%	-33.84%	-110.57%	-1,013.44%	-95.39%	-99.27%	2,496.63%	340.97%	1,204.51%
EPS Growth	-92.50%	1,000.00%	-32.56%	-114.29%	-1,066.67%	-90.91%	-100.00%	1,900.00%	337.93%	575.00%
Operating Cash Flow Growth	436.76%	-43.47%	1,041.93%	-126.54%	159.19%	63.10%	-21.83%	288.75%	49.18%	-1.23%
Free Cash Flow Firm Growth	-550.13%	122.10%	128.83%	103.92%	107.67%	-45.53%	-76.11%	530.11%	264.09%	67.51%
Invested Capital Growth	116.44%	-8.31%	-15.71%	-3.83%	-5.83%	-6.89%	-5.01%	-12.50%	-11.22%	-10.35%
Revenue Q/Q Growth	4.29%	-5.65%	-8.11%	-11.84%	13.51%	6.78%	0.00%	17.18%	4.37%	-0.87%
EBITDA Q/Q Growth	-29.79%	125.92%	-40.07%	-84.81%	584.61%	-26.47%	0.00%	103.87%	41.48%	-32.51%
EBIT Q/Q Growth	-90.25%	2,769.84%	-64.53%	-254.12%	160.98%	-89.99%	0.00%	10,723.87%	70.87%	-41.30%
NOPAT Q/Q Growth	-113.53%	2,435.29%	-60.92%	-226.54%	-6.79%	91.01%	0.00%	1,162.15%	104.73%	-64.45%
Net Income Q/Q Growth	-77.76%	1,356.89%	-33.49%	-104.90%	-1,822.50%	107.35%	0.00%	15,961.29%	93.30%	-60.18%
EPS Q/Q Growth	-78.57%	1,366.67%	-34.09%	-106.90%	-1,350.00%	113.79%	0.00%	0.00%	91.67%	-60.87%
Operating Cash Flow Q/Q Growth	-80.54%	99.15%	78.23%	-138.42%	290.08%	25.32%	0.00%	-7.23%	50.24%	-17.03%
Free Cash Flow Firm Q/Q Growth	6.61%	122.21%	51.65%	-87.54%	82.74%	57.74%	0.00%	228.69%	5.59%	-27.43%
Invested Capital Q/Q Growth	-0.43%	-3.09%	-6.30%	6.36%	-2.49%	-4.18%	0.00%	-2.02%	-1.07%	-3.24%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	85.41%	86.28%	84.74%	84.44%	87.26%	88.06%	88.65%	89.36%	89.99%	85.01%
EBITDA Margin	14.51%	34.74%	19.90%	3.43%	20.67%	14.24%	15.93%	27.72%	37.57%	25.58%
Operating Margin	-0.86%	20.52%	3.37%	-12.97%	5.29%	-0.61%	-2.20%	13.41%	23.25%	12.29%
EBIT Margin	0.72%	21.95%	6.84%	-11.96%	6.43%	0.60%	0.17%	15.63%	25.58%	15.15%
Profit (Net Income) Margin	0.99%	15.23%	11.02%	-0.61%	-10.38%	0.72%	0.09%	11.83%	21.91%	8.80%
Tax Burden Percent	-393.92%	72.51%	187.96%	4.85%	-161.55%	118.69%	51.03%	75.72%	85.66%	58.10%
Interest Burden Percent	-34.69%	95.66%	85.70%	105.61%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	27.49%	-87.96%	0.00%	261.55%	-18.69%	48.97%	24.28%	14.34%	41.90%
Return on Invested Capital (ROIC)	-0.70%	12.60%	5.48%	-7.51%	-6.91%	-0.60%	0.00%	0.00%	0.00%	7.10%
ROIC Less NNEP Spread (ROIC-NNEP)	-1.77%	11.66%	-1.89%	-17.56%	-4.68%	-1.94%	0.00%	0.00%	0.00%	6.17%
Return on Net Nonoperating Assets (RNNOA)	0.56%	-0.86%	0.21%	2.28%	0.67%	0.38%	0.00%	0.00%	0.00%	-1.97%
Return on Equity (ROE)	-0.14%	11.73%	5.69%	-5.23%	-6.23%	-0.22%	0.00%	0.00%	0.00%	5.12%
Cash Return on Invested Capital (CROIC)	-69.31%	14.52%	23.09%	8.24%	8.76%	6.79%	5.14%	13.33%	11.89%	20.17%
Operating Return on Assets (OROA)	0.29%	8.64%	2.67%	-5.08%	2.63%	0.25%	0.00%	0.00%	0.00%	7.58%
Return on Assets (ROA)	0.40%	5.99%	4.29%	-0.26%	-4.26%	0.29%	0.00%	0.00%	0.00%	4.40%
Return on Common Equity (ROCE)	-0.14%	11.73%	5.69%	-5.23%	-6.23%	-0.22%	0.00%	0.00%	0.00%	5.12%
Return on Equity Simple (ROE_SIMPLE)	4.42%	0.00%	5.71%	4.71%	2.81%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-1.07	25	9.73	-12	-13	-1.18	-1.61	17	35	12
NOPAT Margin	-0.60%	14.88%	6.33%	-9.08%	-8.54%	-0.72%	-1.12%	10.15%	19.91%	7.14%
Net Nonoperating Expense Percent (NNEP)	1.07%	0.93%	7.37%	10.05%	-2.23%	1.34%	0.75%	1.21%	1.31%	0.92%
Return On Investment Capital (ROIC_SIMPLE)	-	1.90%	-	-	-	-0.12%	-	-	-	1.15%
Cost of Revenue to Revenue	14.59%	13.72%	15.26%	15.56%	12.74%	11.94%	11.35%	10.64%	10.01%	14.99%
SG&A Expenses to Revenue	63.33%	44.21%	55.67%	64.02%	53.74%	49.47%	60.23%	51.03%	39.70%	45.60%
R&D to Revenue	11.03%	10.62%	13.80%	17.98%	14.72%	14.21%	17.36%	15.56%	16.53%	16.45%
Operating Expenses to Revenue	86.27%	65.76%	81.38%	97.42%	81.97%	88.66%	90.84%	75.95%	66.74%	72.72%
Earnings before Interest and Taxes (EBIT)	1.28	37	11	-16	9.89	0.99	0.24	26	45	26
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	26	58	31	4.65	32	23	23	47	66	45
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.12	2.18	2.16	1.78	1.65	1.72	2.01	1.54	1.71	1.93
Price to Tangible Book Value (P/TBV)	143.10	28.90	17.49	11.66	9.77	7.73	8.02	5.24	4.91	5.03
Price to Revenue (P/Rev)	2.75	2.89	2.95	2.58	2.47	2.60	0.00	0.00	0.00	3.02
Price to Earnings (P/E)	48.07	31.76	37.85	37.78	58.75	1,201.42	0.00	0.00	0.00	27.03
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	2.08%	3.15%	2.64%	2.65%	1.70%	0.08%	0.00%	0.00%	0.00%	3.70%
Enterprise Value to Invested Capital (EV/IC)	2.23	2.38	2.50	1.96	1.81	1.94	2.39	1.78	2.09	2.53
Enterprise Value to Revenue (EV/Rev)	2.63	2.69	2.64	2.32	2.17	2.24	0.00	0.00	0.00	2.40
Enterprise Value to EBITDA (EV/EBITDA)	16.76	11.32	12.25	13.11	11.22	15.05	0.00	0.00	0.00	8.83
Enterprise Value to EBIT (EV/EBIT)	111.00	26.49	32.32	58.19	39.16	262.66	0.00	0.00	0.00	16.25
Enterprise Value to NOPAT (EV/NOPAT)	71.25	38.96	37.82	44.17	63.55	0.00	0.00	0.00	0.00	25.80
Enterprise Value to Operating Cash Flow (EV/OCF)	12.58	15.37	10.92	20.50	14.15	12.26	0.00	0.00	0.00	9.25
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	15.70	9.90	23.25	20.02	27.53	45.38	12.46	16.56	11.85
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.53	0.48	0.53	0.02	0.05	0.06	0.06	0.05	0.05	0.05
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.32	-0.07	-0.11	-0.13	-0.14	-0.19	-0.25	-0.25	-0.28	-0.32
Leverage Ratio	1.95	1.99	1.97	1.70	1.69	1.65	1.68	1.39	1.37	1.35
Compound Leverage Factor	-0.68	1.91	1.69	1.79	1.69	1.65	1.68	1.39	1.37	1.35
Debt to Total Capital	34.49%	32.31%	34.52%	2.20%	4.79%	5.35%	5.24%	4.71%	4.42%	4.37%
Short-Term Debt to Total Capital	34.49%	32.31%	34.52%	2.20%	4.79%	5.35%	5.24%	4.71%	4.42%	4.37%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	65.51%	67.69%	65.48%	97.80%	95.21%	94.65%	94.76%	95.29%	95.58%	95.63%
Debt to EBITDA	4.34	2.67	3.34	0.18	0.39	0.58	0.00	0.00	0.00	0.26
Net Debt to EBITDA	-0.72	-0.83	-1.43	-1.50	-1.52	-2.43	0.00	0.00	0.00	-2.26
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	18.43	9.18	10.31	0.62	2.20	-20.79	0.00	0.00	0.00	0.77
Net Debt to NOPAT	-3.07	-2.87	-4.41	-5.06	-8.60	87.62	0.00	0.00	0.00	-6.59
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	2.02	2.31	2.23	3.78	3.60	3.86	3.71	3.32	4.06	5.07
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.91	1.07	1.21	1.68	1.56	1.70	1.73	1.91	2.20	2.35
Quick Ratio	0.77	0.91	0.51	1.14	1.19	1.38	1.42	1.62	1.88	2.04
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-420	93	141	18	32	51	34	111	117	85
Operating Cash Flow to CapEx	9,415.65%	0.00%	17,671.22%	-11,870.44%	23,916.67%	0.00%	15,484.27%	55,662.50%	26,760.00%	20,847.89%
Free Cash Flow to Firm to Interest Expense	-243.43	58.49	93.94	19.36	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	8.03	17.29	32.64	-20.74	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	7.94	17.30	32.46	-20.92	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.41	0.39	0.39	0.42	0.41	0.41	0.00	0.00	0.00	0.50
Accounts Receivable Turnover	4.43	4.24	4.63	4.30	3.99	3.92	0.00	0.00	0.00	4.62
Inventory Turnover	1.13	0.98	1.03	1.06	1.05	0.99	0.00	0.00	0.00	1.18
Fixed Asset Turnover	0.00	0.00	42.01	0.00	0.00	42.33	0.00	0.00	0.00	52.79
Accounts Payable Turnover	0.89	0.82	1.00	0.86	0.92	0.95	0.00	0.00	0.00	1.00
Days Sales Outstanding (DSO)	82.47	86.00	78.82	84.81	91.42	93.02	0.00	0.00	0.00	78.93
Days Inventory Outstanding (DIO)	321.88	371.40	354.07	342.83	349.15	368.03	0.00	0.00	0.00	308.52
Days Payable Outstanding (DPO)	410.07	447.82	363.58	422.22	395.51	383.20	0.00	0.00	0.00	365.26
Cash Conversion Cycle (CCC)	-5.72	9.58	69.31	5.41	45.06	77.85	0.00	0.00	0.00	22.19
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	778	754	707	751	733	702	671	658	651	629
Invested Capital Turnover	1.16	0.85	0.87	0.83	0.81	0.83	0.00	0.00	0.00	0.99
Increase / (Decrease) in Invested Capital	419	-68	-132	-30	-45	-52	-35	-94	-82	-73
Enterprise Value (EV)	1,736	1,796	1,764	1,469	1,326	1,362	1,606	1,171	1,362	1,590
Market Capitalization	1,811	1,928	1,970	1,638	1,505	1,581	1,864	1,471	1,718	1,997
Book Value per Share	$15.94	$16.39	$16.77	$16.89	$16.71	$16.87	$17.01	$17.42	$18.28	$18.76
Tangible Book Value per Share	$0.24	$1.23	$2.07	$2.58	$2.82	$3.75	$4.25	$5.11	$6.35	$7.19
Total Capital	1,302	1,309	1,393	941	958	974	981	1,005	1,054	1,083
Total Debt	449	423	481	21	46	52	51	47	47	47
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-75	-132	-206	-168	-179	-219	-258	-300	-357	-406
Capital Expenditures (CapEx)	0.15	-0.01	0.28	0.16	0.15	-0.04	0.25	0.06	0.20	0.21
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-4.86	7.95	0.33	40	7.52	0.11	-17	-18	-8.13	-13
Debt-free Net Working Capital (DFNWC)	387	469	633	192	208	255	281	330	395	441
Net Working Capital (NWC)	-62	46	152	171	162	203	230	282	348	394
Net Nonoperating Expense (NNE)	-2.82	-0.58	-7.22	-11	2.83	-2.36	-1.73	-2.83	-3.51	-2.89
Net Nonoperating Obligations (NNO)	-75	-132	-206	-168	-179	-219	-258	-300	-357	-406
Total Depreciation and Amortization (D&A)	24	21	20	21	22	22	23	20	21	18
Debt-free, Cash-free Net Working Capital to Revenue	-0.74%	1.19%	0.05%	6.31%	1.23%	0.02%	0.00%	0.00%	0.00%	-1.90%
Debt-free Net Working Capital to Revenue	58.72%	70.33%	94.64%	30.23%	34.02%	41.97%	0.00%	0.00%	0.00%	66.64%
Net Working Capital to Revenue	-9.42%	6.92%	22.71%	26.96%	26.51%	33.40%	0.00%	0.00%	0.00%	59.48%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.03	$0.47	$0.31	($0.02)	($0.29)	$0.02	$0.00	$0.36	$0.70	$0.28
Adjusted Weighted Average Basic Shares Outstanding	53.79M	53.67M	54.38M	54.50M	54.61M	54.54M	54.80M	54.98M	55.15M	55.10M
Adjusted Diluted Earnings per Share	$0.03	$0.44	$0.29	($0.02)	($0.29)	$0.04	$0.00	$0.36	$0.69	$0.27
Adjusted Weighted Average Diluted Shares Outstanding	55.03M	61.68M	62.45M	54.50M	54.61M	55.51M	55.63M	55.72M	56.02M	55.96M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	54.06M	54.38M	54.48M	54.59M	54.63M	0.00	54.97M	55.11M	55.22M	55.81M
Normalized Net Operating Profit after Tax (NOPAT)	-0.73	23	2.47	-12	5.38	-0.84	-2.17	14	34	13
Normalized NOPAT Margin	-0.41%	13.84%	1.61%	-8.67%	3.49%	-0.51%	-1.51%	8.19%	19.42%	7.26%
Pre Tax Income Margin	-0.25%	21.00%	5.86%	-12.63%	6.43%	0.60%	0.17%	15.63%	25.58%	15.15%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.74	23.05	6.99	-17.82	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-0.62	15.62	6.46	-13.53	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.66	23.05	6.81	-18.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-0.70	15.63	6.28	-13.70	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Supernus Pharmaceuticals' Financials

When does Supernus Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Supernus Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Supernus Pharmaceuticals' net income changed over the last 10 years?

Supernus Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of $73.87 million in 2024, falling from -$10.93 million in 2014. The previous period was $1.32 million in 2023. View Supernus Pharmaceuticals' forecast to see where analysts expect Supernus Pharmaceuticals to go next.

What is Supernus Pharmaceuticals's operating income?

Supernus Pharmaceuticals's total operating income in 2024 was $81.67 million, based on the following breakdown:

Total Gross Profit: $583.91 million
Total Operating Expenses: $502.25 million

How has Supernus Pharmaceuticals revenue changed over the last 10 years?

Over the last 10 years, Supernus Pharmaceuticals' total revenue changed from $92.68 million in 2014 to $661.82 million in 2024, a change of 614.1%.

How much debt does Supernus Pharmaceuticals have?

Supernus Pharmaceuticals' total liabilities were at $332.34 million at the end of 2024, a 6.7% decrease from 2023, and a 245.9% increase since 2014.

How much cash does Supernus Pharmaceuticals have?

In the past 10 years, Supernus Pharmaceuticals' cash and equivalents has ranged from $33.50 million in 2015 to $288.64 million in 2020, and is currently $69.33 million as of their latest financial filing in 2024.

How has Supernus Pharmaceuticals' book value per share changed over the last 10 years?

Over the last 10 years, Supernus Pharmaceuticals' book value per share changed from 0.95 in 2014 to 18.76 in 2024, a change of 1,878.6%.

Related Companies

This page (NASDAQ:SUPN) was last updated on 5/6/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Supernus Pharmaceuticals (SUPN) Financials

Frequently Asked Questions About Supernus Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Supernus Pharmaceuticals (SUPN) Financials

Annual Income Statements for Supernus Pharmaceuticals

Quarterly Income Statements for Supernus Pharmaceuticals

Annual Cash Flow Statements for Supernus Pharmaceuticals

Quarterly Cash Flow Statements for Supernus Pharmaceuticals

Annual Balance Sheets for Supernus Pharmaceuticals

Quarterly Balance Sheets for Supernus Pharmaceuticals

Annual Metrics and Ratios for Supernus Pharmaceuticals

Quarterly Metrics and Ratios for Supernus Pharmaceuticals

Frequently Asked Questions About Supernus Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools